Sucampo receive Japanese approval for AMITIZA Sucampo Pharmaceuticals.

Abbott, Sucampo receive Japanese approval for AMITIZA Sucampo Pharmaceuticals, Inc. and Abbott announced that Sucampo Pharma today, Ltd . Related StoriesScripps Florida researchers earn $2.4 million to broaden development of new suffering therapies ‘We are very very happy to receive Japan’s first-ever acceptance for a prescription drugs for chronic constipation as it helps us achieve our objective of bringing medications with novel mechanisms of actions to patients with unmet medical needs on a global basis,’ said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and CEO. ‘We look forward to dealing with Abbott to meet the needs of the patients in Japan.’ In 2009 2009, Sucampo and Abbott Japan Co. Ltd. Entered into a license, supply and commercialization contract for AMITIZA in Japan..

For the very first time, Abbott offers earnings-per-share assistance for the third-quarter 2008 of $0.76 – $0.78, excluding specified items, the midpoint of which reflects growth of around 15 %. Abbott continues to forecast net specified items for the full-year 2008 of $0.08 per talk about, associated with cost reduction initiatives and acquired in-process R&D primarily, offset by favorable items including an increase related to the final outcome of the TAP joint venture, a favorable settlement of a prior year’s IRS tax audit, and a gain on the sale of an equity expense. Including these specified items, projected earnings per share under GAAP will be $3.16 – $3.20 for the full-year 2008.